<DOC>
	<DOCNO>NCT01123278</DOCNO>
	<brief_summary>Hypogonadism ( HG ) frequently complicate Metabolic Syndrome ( MetS ) , whether testosterone replacement ( TRT ) beneficial clearly ascertain . This study design address effect TRT insulin resistance , body composition pro-inflammatory status naïve patient MetS HG .</brief_summary>
	<brief_title>Testosterone Replacement Metabolic Syndrome Inflammation</brief_title>
	<detailed_description>The feature Metabolic Syndrome ( MetS ) include abdominal obesity , atherogenic dyslipidemia , raise blood pressure , insulin resistance glucose intolerance . These symptom also frequently find hypogonadal men . Adipose tissue androgens male obesity reciprocally link . Total free testosterone ( T ) decrease proportion degree body fatness T regulate insulin sensitivity body composition . As consequence , hypoandrogenism carry additional independent risk cardiovascular metabolic disorder . Men type 2 diabetes mellitus ( T2D ) exhibit lower T level inversely correlate HbA1c . In addition , abdominal adiposity cause impairment testicular steroidogenesis directly link circulating adipokines ; enhance cytokine release macrophage-infiltrated adipose tissue pivotal pathogenesis insulin resistance atherosclerosis . Both MetS T2D share hypogonadism proinflammatory state . For reason perform randomize control trial effect TRT insulin resistance circulate inflammatory marker cohort middle-aged men mild hypogonadism MetS first diagnosis , take medication know influence investigate outcomes . We establish strict criterion enrollment use physiological replace therapy . Given testosterone replacement therapy ( TRT ) determine reduction body fat mass parallel increase fat free mass ( 6 ) , TRT exert anti-inflammatory role inhibiting interleukin ( IL ) , particular IL-6 gene ( 14 ) , remain establish whether independent effect also reflect improvement insulin resistance .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>patient Metabolic Syndrome accord ATPIII patient mild hypogonadism ( testosterone evaluation 6 11 nmol/L ) patient naïve hypoglycemic therapy patient hypoglycemic medication patient severe hypogonadism ( &lt; 5 nmol/L ) patient borderline T value hypogonadism ( &gt; 11 nmol/L ) patient contraindication testosterone therapy : prostate cancer , PSA &gt; 4 ng/ml , severe hepatic renal insufficiency , Hb &gt; 17 , Htc &gt; 52 % , severe urinary retention</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Adiponectin</keyword>
	<keyword>Resistin</keyword>
	<keyword>Adipocytes</keyword>
	<keyword>Testosterone</keyword>
	<keyword>Aging</keyword>
	<keyword>HOMA-IR</keyword>
	<keyword>Insulin</keyword>
	<keyword>Hypogonadism</keyword>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>Obesity</keyword>
	<keyword>Erectile Dysfunction</keyword>
</DOC>